How should clinical labs address CACT and CPT-2 deficiency overlap in screening workflows?

Nearly identical biochemical footprints pose a diagnostic dilemma for newborn screening programs. Carnitine-Acylcarnitine Translocase (CACT) deficiency and Carnitine Palmitoyl Transferase 2 (CPT-2) deficiency both produce a classic long-chain acylcarnitine signature on tandem mass spectrometry (MS/MS): marked elevations of C16 and C18:1 acylcarnitines alongside low free carnitine. Because this profile is biochemically indistinguishable between the two conditions, laboratories must design a multi-tiered workflow that starts by flagging a combined risk for CACT/CPT-2 disorders and then rapidly deploys orthogonal confirmatory tests—most commonly enzymatic assays in fibroblasts or targeted DNA sequencing—to resolve the diagnosis.

The central challenge is that MS/MS-based newborn screening cannot separate CACT from CPT-2 deficiency. The safest and most efficient strategy is to treat every suspicious profile as a signal for both defects and let a second-tier reflex test establish the exact molecular cause, ensuring no affected infant is missed while preventing irreversible harm from delayed treatment.

Why Identical Acylcarnitine Patterns Trap Screening Laboratories

The One-Size-Fits-All Metabolic Signal

Both CACT and CPT-2 are essential for long-chain fatty acid transport into mitochondria. When either protein is dysfunctional, fatty acid oxidation stalls, and the corresponding acylcarnitines accumulate in the blood. The primary marker pattern—elevated hexadecanoylcarnitine (C16) and octadecenoylcarnitine (C18:1)—is so consistent that it has become the universal red flag in screening programs.

The problem is that this profile offers no discriminating power. The same ratios, the same degree of free carnitine depletion, and the same secondary metabolite changes appear regardless of whether the block occurs at the membrane (CACT) or inside the matrix (CPT-2). MS/MS simply reports the sum of what has backed up, not where the traffic jam is.

Why This Overlap Is More Dangerous Than It Looks

A false-positive result causes parental anxiety and unnecessary follow-up, but a missed differential diagnosis can be lethal. Newborns with either disorder are vulnerable to hypoketotic hypoglycemia, cardiomyopathy, and sudden death during fasting or illness. If a laboratory reports only “risk for CPT-2 deficiency” based on an incomplete algorithm, a CACT patient may be managed incorrectly—or worse, discharged with a false sense of security if the CPT-2 test comes back negative.

The deep need, therefore, is not just to spot an abnormal profile but to build a system that prevents diagnostic anchoring and ensures that every high-risk newborn is fully investigated for both defects simultaneousely.

Building a Reflex-Based, Two-Tiered Workflow

Tier 1: Universal Flagging as a Combined Disorder

The initial screening kit should be configured to recognize the C16/C18:1 elevation pattern as a joint CACT/CPT-2 risk, not as a hint toward one disease. This means the laboratory information system (LIS) must bypass any attempt to rank likelihoods based on MS/MS data alone.

A well-designed LIS rule will immediately trigger a positive screen for “CACT/CPT-2 deficiency spectrum” whenever the C16 and C18:1 levels cross predefined cutoffs and the free carnitine drops below a threshold. This approach eliminates the risk of a false-negative due to premature triage and aligns with the universal recommendation to treat long-chain fatty acid oxidation disorders as an urgent category.

Tier 2: Instantaneous Reflex to Confirmatory Testing

Once the combined flag is raised, the next step must happen without delay. Laboratories should have a pre-established protocol for reflex testing that moves directly from the dried blood spot to a definitive diagnostic method. The two main options are:

• Enzymatic assay in cultured skin fibroblasts: This measures the specific activity of CACT and CPT-2 directly. It remains the gold standard because it reveals which transporter is impaired, and it can also quantify residual function—information that guides prognosis.
• Targeted next-generation sequencing (NGS) panel: A panel that covers both the SLC25A20 gene (encoding CACT) and the CPT2 gene can rapidly identify pathogenic variants. If biallelic pathogenic mutations are found in one gene and not the other, the diagnosis is resolved.

In many high-throughput screening centers, the workflow is automated: the abnormal MS/MS result automatically generates a request for the second-tier test, minimizing hand-offs and the chance of a lost-to-follow-up infant.

Understanding the Trade-offs and Common Pitfalls

No reflex strategy is perfect. Recognizing the limitations is essential to designing a workflow that is both clinically sound and operationally feasible.

Enzymatic Assays – The Gold Standard with a Time Penalty

Fibroblast culture takes weeks. While the diagnostic accuracy of direct enzyme measurement is unparalleled, the delay can be dangerous for a neonate who needs immediate management. Laboratories must therefore couple the enzymatic test with interim clinical guidance—instructing families and physicians to treat the baby as if both disorders are present (avoid fasting, monitor glucose and cardiac function) until the result returns.

DNA Sequencing – Speed at the Price of Uncertainty

An NGS panel can deliver an answer in days, but it comes with the headache of variant interpretation. A novel missense variant in SLC25A20 or CPT2 might be classified as a variant of uncertain significance (VUS), leaving the laboratory in a gray zone. In such cases, enzyme testing is often still needed to resolve the functional impact. Additionally, sequencing may miss deep intronic mutations or large deletions unless specifically designed to capture them.

The Hidden Risk of Diagnostic Creep

Another pitfall is assuming that a negative second-tier result closes the case. If a laboratory receives a negative CPT-2 sequencing result but has not simultaneously tested for CACT, the infant could be falsely declared healthy. The workflow must be baked into the ordering interface so that any molecular test ordered for this profile automatically includes both genes. Paper-based requests or ad-hoc orders are fertile ground for this type of error.

Making the Right Choice for Your Laboratory’s Goal

Every screening program operates under unique constraints—budget, turnaround time expectations, and the availability of specialty laboratories. Here is how to tailor the approach.

• If your primary focus is maximum diagnostic certainty: Build the workflow around a reflex to fibroblast enzyme testing, and implement a standard interim management protocol for all flagged infants to bridge the long turnaround time.
• If your primary focus is speed and early discharge from follow-up: Opt for a rapid, dual-gene NGS panel from a fresh blood or dried spot sample, but ensure that any VUS is automatically escalated to parental testing or enzyme analysis to avoid ambiguous reports.
• If resource constraints limit access to enzyme or sequencing services: Create a centralized referral network where the screening laboratory immediately sends a sample to a reference lab equipped to run both confirmatory tests in parallel, and use an IT bridge to guarantee that a negative result for one disorder never masks the other.
• If you are designing the screening algorithm from scratch: Hard-code the combined CACT/CPT-2 flag into your LIS as a non-negotiable rule; never allow the system to split the differential based on MS/MS ratio cutoffs that are inevitably unreliable.

The biochemical overlap between CACT and CPT-2 deficiency is not a weakness of the screening technology—it is a predictable feature of mitochondrial fatty acid transport defects. By building a workflow that treats the overlap as a starting point rather than an obstacle, clinical laboratories can convert a diagnostic blind spot into a model of safety and precision.

Summary Table:

Optimizing your metabolic screening workflows or developing next-generation IVD assays? CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to high-quality IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. Contact CamelBio today to enhance your assay accuracy and streamline laboratory performance!